BACKGROUND: The Tyr978X BRCA1 mutation is a founder mutation detected in high-risk Iraqi-Iranian Jewish families as well as in the general non-Ashkenazi population. The same mutation was also reported in non-Jewish high-risk women from Canada. Its occurrence in non-Jewish individuals from Iran has never been tested. OBJECTIVE: Assess the occurrence rate of Tyr978X BRCA1 germline mutation in the general population of Iranian non- Jewish individuals and compare the BRCA1-linked haplotype of Jewish and non-Jewish mutation carriers. METHODS: PCR amplification of the relevant fragment of the BRCA1 gene, followed by restriction enzyme digestion that differentiates wild type from mutant allele. For haplotyping, 7 BRCA1-linked markers were used. The tested population included 442 apparently healthy Iranian non-Jewish individuals, and 17 mutation carriers from Israel and Canada. RESULTS: The Tyr978X BRCA1 mutation was not detected in any Iranian non-Jewish individual. The intragenic haplotype of all Jewish Israeli mutation carriers was identical, but differed from that of Canadian non-Jews in two intragenic markers. CONCLUSIONS: The Tyr978X BRCA1 mutation which is a founder mutation in Jews, may be a hot spot in non-Jewish high risk women, and probably does not represent a rare sequence variant in Iranian non-Jews.
BACKGROUND: The Tyr978X BRCA1 mutation is a founder mutation detected in high-risk Iraqi-Iranian Jewish families as well as in the general non-Ashkenazi population. The same mutation was also reported in non-Jewish high-risk women from Canada. Its occurrence in non-Jewish individuals from Iran has never been tested. OBJECTIVE: Assess the occurrence rate of Tyr978X BRCA1 germline mutation in the general population of Iranian non- Jewish individuals and compare the BRCA1-linked haplotype of Jewish and non-Jewish mutation carriers. METHODS: PCR amplification of the relevant fragment of the BRCA1 gene, followed by restriction enzyme digestion that differentiates wild type from mutant allele. For haplotyping, 7 BRCA1-linked markers were used. The tested population included 442 apparently healthy Iranian non-Jewish individuals, and 17 mutation carriers from Israel and Canada. RESULTS: The Tyr978X BRCA1 mutation was not detected in any Iranian non-Jewish individual. The intragenic haplotype of all Jewish Israeli mutation carriers was identical, but differed from that of Canadian non-Jews in two intragenic markers. CONCLUSIONS: The Tyr978X BRCA1 mutation which is a founder mutation in Jews, may be a hot spot in non-Jewish high risk women, and probably does not represent a rare sequence variant in Iranian non-Jews.
Authors: R B Barkardottir; L Sarantaus; A Arason; P Vehmanen; P O Bendahl; T Kainu; K Syrjäkoski; R Krahe; P Huusko; S Pyrhönen; K Holli; O P Kallioniemi; V Egilsson; J Kere; H Nevanlinna Journal: Eur J Hum Genet Date: 2001-10 Impact factor: 4.246
Authors: A P Manning; D Abelovich; P Ghadirian; J A Lambert; D Frappier; D Provencher; A Robidoux; T Peretz; S A Narod; A M Mes-Masson; W D Foulkes; T Wang; K Morgan; T M Fujiwara; P N Tonin Journal: Hum Hered Date: 2001 Impact factor: 0.444
Authors: S L Neuhausen; A K Godwin; R Gershoni-Baruch; E Schubert; J Garber; D Stoppa-Lyonnet; E Olah; B Csokay; O Serova; F Lalloo; A Osorio; M Stratton; K Offit; J Boyd; M A Caligo; R J Scott; A Schofield; E Teugels; M Schwab; L Cannon-Albright; T Bishop; D Easton; J Benitez; M C King; B A Ponder; B Weber; P Devilee; A Borg; S A Narod; D Goldgar Journal: Am J Hum Genet Date: 1998-06 Impact factor: 11.025
Authors: B Modan; P Hartge; G Hirsh-Yechezkel; A Chetrit; F Lubin; U Beller; G Ben-Baruch; A Fishman; J Menczer; J P Struewing; M A Tucker; S Wacholder Journal: N Engl J Med Date: 2001-07-26 Impact factor: 91.245
Authors: R. Shiri-Sverdlov; R. Gershoni-Baruch; G. Ichezkel-Hirsch; W.H. Gotlieb; R. Bruchim Bar-Sade; A. Chetrit; S. Rizel; B. Modan; E. Friedman Journal: Community Genet Date: 2001-07
Authors: D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman Journal: Am J Hum Genet Date: 1998-03 Impact factor: 11.025
Authors: S L Neuhausen; S Mazoyer; L Friedman; M Stratton; K Offit; A Caligo; G Tomlinson; L Cannon-Albright; T Bishop; D Kelsell; E Solomon; B Weber; F Couch; J Struewing; P Tonin; F Durocher; S Narod; M H Skolnick; G Lenoir; O Serova; B Ponder; D Stoppa-Lyonnet; D Easton; M C King; D E Goldgar Journal: Am J Hum Genet Date: 1996-02 Impact factor: 11.025
Authors: L Theodor; R Bar-Sade; A Kruglikova; G Ben-Baruch; S Risel; R Shiri-Sverdlov; G Hirsh Yechezkel; B Modan; M Z Papa; G Rechavi; E Friedman Journal: Br J Cancer Date: 1998-06 Impact factor: 7.640